119 The MICORDIS study Figure 2A shows the results of the MCE measurements at baseline, hyperinsulinemia and dobutamine-induced stress in ANOCA patients and healthy controls. Overall MBV was significantly lower under all three conditions in ANOCA patients versus healthy controls (baseline MBV: 0.388 ± 0.077 mL/mL vs 0.438 ± 0.100 mL/mL, respectively p = 0.041, hyperinsulinemia MBV: 0.395 ± 0.073 mL/mL vs 0.447 ± 0.086 mL/mL, respectively p = 0.021, dobutamine-induced stress MBV: 0.401 ± 0.14 mL/mL vs 0.476 ± 0.092 mL/ mL, respectively p = 0.030). The same findings for MBV applied when stratified according to perfusion territory (Supplemental Figure 3). There was no difference in MVR between ANOCA patients and healthy controls in response to hyperinsulinemia (0.992 [0.859–1.199] vs 1.016 [0.847–1.179], respectively p = 0.859) and to dobutamine-induced stress (1.006 [0.680–1.253 vs 1.106 [0.947–1.357], respectively p = 0.194) (Figure 3A). Table 2. Baseline characteristics ANOCA-patients Total Women Men p-value Total number of patients n = 28 n = 22 n = 6 Demographics Age, yrs 56.8 ±8.6 57.1 ±9.2 55.7 ±6.8 0.719 BMI, kg/m2 27.6 ±4.5 27.4 ±4.1 28.5 ±5.8 0.585 Ejection fraction, % 62.4 ±5.5 62.3 ±5.9 62.5 ±4.6 0.945 Ischemic symptoms Chest discomfort, % 23 (39.3) 17 (77.3) 6 (100) 0.553 Shortness of breath, % 17 (60.7) 11 (50.0) 6 (100) 0.055 Fatigue, % 15 (53.6) 11 (50) 4 (66.7) 0.655 Other (i.e. palpitations), % 2 (7.1) 2 (9.1) 0 (0) 1.00 Classification of Angina Pectoris 0.482 Typical, % 7 (25.0) 6 (27.3) 1 (16.7) Atypical, % 18 (64.3) 13 (59.1) 5 (83.3) Aspecific, % 3 (10.7) 3 (13.6) 0 (0) NYHA classification 0.290 NYHA I, % 4 (14.3) 2 (9.1) 2 (33.3) NYHA II, % 16 (57.1) 14 (63.6) 2 (33.3) NYHA III, % 6 (21.4) 4 (18.2) 2 (33.3) NYHA IV, % 2 (7.1) 2 (9.1) 0 (0) Diamond and Forrester score 0.634 Low 18 (64.3) 15 (68.2) 3 (50.0) Middle 10 (35.7) 7 (31.8) 3 (50.0) High 0 (0) 0 (0) 0 (0) Medication at study admission ACE-inhibitors, % 13 (48.1) 11 (52.4) 2 (33.3) 0.648 Anticoagulants, % 16 (59.3) 11 (52.4) 5 (83.3) 0.174 6
RkJQdWJsaXNoZXIy MTk4NDMw